Burning Rock Biotech Limited (NASDAQ:BNR) Sees Significant Decrease in Short Interest

Burning Rock Biotech Limited (NASDAQ:BNR) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 72,300 shares, a decline of 10.3% from the November 15th total of 80,600 shares. Based on an average daily trading volume, of 33,600 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.9% of the shares of the stock are sold short.

Burning Rock Biotech Stock Down 0.4 %

NASDAQ:BNR traded down $0.03 during mid-day trading on Tuesday, reaching $6.70. 6,122 shares of the company were exchanged, compared to its average volume of 13,930. Burning Rock Biotech has a 12 month low of $2.62 and a 12 month high of $9.99. The company has a fifty day moving average of $4.33 and a 200 day moving average of $5.34. The stock has a market cap of $68.63 million, a PE ratio of -2.23 and a beta of 0.60.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.